{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:49:13Z","timestamp":1792633753339,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00198-015-3164-4","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T14:39:48Z","timestamp":1432737588000},"page":"2479-2489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study"],"prefix":"10.1007","volume":"26","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Feudjo Tepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kalouche-Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"key":"3164_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"3164_CR2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"3164_CR3","first-page":"25","volume":"3","author":"A Hoer","year":"2009","unstructured":"Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Haussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25\u201330","journal-title":"Patient Prefer Adherence"},{"key":"3164_CR4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"3164_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3\u2013S13","journal-title":"Am J Med"},{"key":"3164_CR6","first-page":"A567","volume":"16","author":"P Lakatos","year":"2013","unstructured":"Lakatos P, T\u00f3th E, Lang Z, Psachoulia E, Intorcia M (2013) Compliance protects against fracture in women with postmenopausal osteoporosis in Hungary. Value Health 16:A567","journal-title":"Value Health"},{"key":"3164_CR7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1185\/030079906X132370","volume":"22","author":"CH Boogaard van den","year":"2006","unstructured":"van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757\u20131764","journal-title":"Curr Med Res Opin"},{"key":"3164_CR8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","volume":"22","author":"JC Netelenbos","year":"2011","unstructured":"Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis\u2014a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22:1537\u20131546","journal-title":"Osteoporos Int"},{"key":"3164_CR9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018","journal-title":"Lancet"},{"key":"3164_CR10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.smj.0000221637.90495.66","volume":"99","author":"TW Downey","year":"2006","unstructured":"Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570\u2013575","journal-title":"South Med J"},{"key":"3164_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303\u2013310","journal-title":"Joint Bone Spine"},{"key":"3164_CR12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00774-004-0508-0","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M et al (2004) Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 22:462\u2013468","journal-title":"J Bone Miner Metab"},{"key":"3164_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3904\/kjim.2011.26.3.340","volume":"26","author":"YH Lee","year":"2011","unstructured":"Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340\u2013347","journal-title":"Korean J Intern Med"},{"key":"3164_CR14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"3164_CR15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-013-2515-2","volume":"25","author":"P Hadji","year":"2014","unstructured":"Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A (2014) The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int 25:339\u2013347","journal-title":"Osteoporos Int"},{"key":"3164_CR16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5414\/CP201931","volume":"51","author":"PKS Hadji","year":"2013","unstructured":"Hadji PKS, H\u00e4ussler B, Kless T, Linder R, Rowinski-Jablokow M, Verheyen F, Gothe H (2013) The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 51:868\u2013872","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3164_CR17","first-page":"A567","volume":"16","author":"P Lakatos","year":"2013","unstructured":"Lakatos P, T\u00f3th E, Cina Z, Lang Z, Psachoulia E, Intorcia M (2013) Persistence & compliance to treatment for osteoporosis in postmenopausal women in Hungary: a retrospective cohort study. Value Health 16:A567\u2013A568","journal-title":"Value Health"},{"key":"3164_CR18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00198-011-1834-4","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH (2012) Quality of life and health status with zoledronic acid and generic alendronate\u2014a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int 23:2043\u20132051","journal-title":"Osteoporos Int"},{"key":"3164_CR19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741\u2013753","journal-title":"Osteoporos Int"},{"key":"3164_CR20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"3164_CR21","unstructured":"Amgen (2014) Prolia\u00ae EU Summary of Product Characteristics [Available at: https:\/\/www.medicinesorguk\/ema\/medicine\/23127 ]. Accessed November 2014"},{"key":"3164_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"3164_CR23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"3164_CR24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"3164_CR25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00198-007-0410-4","volume":"18","author":"F Lekkerkerker","year":"2007","unstructured":"Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311\u20131317","journal-title":"Osteoporos Int"},{"key":"3164_CR26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348\u2013354","journal-title":"J Clin Hypertens"},{"key":"3164_CR27","author":"SL Silverman","year":"2014","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I et al (2014) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. doi: 10.1007\/s00198-014-2871-6","journal-title":"Osteoporos Int"},{"key":"3164_CR28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149\u20132157","journal-title":"J Clin Endocrinol Metab"},{"key":"3164_CR29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","volume":"47","author":"HK Genant","year":"2010","unstructured":"Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M et al (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131\u2013139","journal-title":"Bone"},{"key":"3164_CR30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"3164_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","volume":"24","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2012) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24:209\u2013217","journal-title":"Osteoporos Int"},{"key":"3164_CR32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","volume":"82","author":"P Kothawala","year":"2007","unstructured":"Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493\u20131501","journal-title":"Mayo Clin Proc"},{"key":"3164_CR33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","volume":"75","author":"J Compston","year":"2013","unstructured":"Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392\u2013396","journal-title":"Maturitas"},{"key":"3164_CR34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-0037-1619980","volume":"20","author":"Dachverband Osteologie","year":"2011","unstructured":"Dachverband Osteologie (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20:55\u201374","journal-title":"Osteologie"},{"key":"3164_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357","journal-title":"Osteoporos Int"},{"key":"3164_CR36","first-page":"38","volume":"12","author":"P Makras","year":"2012","unstructured":"Makras P, Vaiopoulos G, Lyritis GP (2012) 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38\u201342","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"3164_CR37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper J, Stenmark EV, McCloskey EV, J\u00f6nsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"3164_CR38","unstructured":"ISPOR (2008) ISPOR global health care systems road map: Greece [ http:\/\/www.ispor.org\/htaroadmaps\/Greece.asp ]. Accessed March 2015"},{"key":"3164_CR39","unstructured":"Institut national d\u2019assurance maladie-invalidit\u00e9 (2014) Liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables : les cat\u00e9gories de remboursement [ http:\/\/www.inami.fgov.be\/fr\/themes\/cout-remboursement\/par-mutualite\/medicament-produits-sante\/remboursement\/specialites\/Pages\/liste-specialites-pharmaceutiques-remboursables-categories-remboursement.aspx#.VRExb8JybGg ]. Accessed March 2015"},{"key":"3164_CR40","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943\u20131951","journal-title":"Osteoporos Int"},{"key":"3164_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"3164_CR42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896\u2013905","journal-title":"Int J Clin Pract"},{"key":"3164_CR43","doi-asserted-by":"crossref","first-page":"A567","DOI":"10.1016\/j.jval.2013.08.1515","volume":"16","author":"L Karlsson","year":"2013","unstructured":"Karlsson L, Lundkvist J, Intorcia M, Psachoulia E, Strom O (2013) Treatment persistence in Swedish women initiating denosumab treatment for postmenopausal osteoporosis. Value Health 16:A567","journal-title":"Value Health"},{"key":"3164_CR44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3164-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3164-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T17:04:00Z","timestamp":1566752640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3164-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,28]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["3164"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3164-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,28]]}}}